Table 2.
Baseline characteristics of hemodialysis patients with SARS COV2 infection.
| ALL | SURVIVORS | DECEASED | P | |
|---|---|---|---|---|
| Total (n) | 131 | 104 | 27 | |
| Age in years (n) (median; range) | 50 (19-80) | 49 (19-76) | 56 (21-80) | 0.0047 |
| Male: n (%) | 75 (57%) | 58 (56%) | 17 (63%) | 0.5017 |
| Female: n (%) | 56 (43%) | 46 (44%) | 10 (37%) | |
| Co morbidities: n (%) | ||||
| Hypertension | 99 (76%) | 77 (74%) | 22 (81%) | 0.425 |
| DM | 38 (29%) | 23 (22%) | 15 (56%) | 0.001 |
| CAD | 29 (22%) | 20 (19%) | 9 (33%) | 0.1201 |
| Underlying Respiratory illness | 11 (8%) | 8 (77%) | 3 (11%) | 0.570 |
| HBV | 0 | 0 | 0 | |
| HIV | 0 | 0 | 0 | |
| HCV | 5 (4%) | 4 (4%) | 1 (4%) | |
| Hypothyroidism | 6 (5%) | 6 (6%) | 0 | |
| Renal Allograft Failure | 2 (1.5%) | 2 (2%) | 0 | |
| Dialysis Vintage in years (median; Range) | 2 (0.1-14) | 2 (0.1-14) | 2 (0.4-12) | 0.807 |
| Dialysis Access: n (%) | ||||
| Arterio-venous fistula | 98 (75%) | 76 (73%) | 22 (81%) | 0.373 |
| Dialysis Catheter | 33 (25%) | 28 (27%) | 5 (18.5%) | |
| Double Lumen catheter | 13 (10%) | 10 (10%) | 3 (11%) | |
| Tunnelled cuffed Catheter | 20 (15%) | 18 (17%) | 2 (7%) | |
| Frequency of dialysis [Before referral to us] | 0.757 | |||
| 3/WK: n (%) | 84 (64%) | 66 (63%) | 18 (67%) | |
| <3/WK: n (%) | 47 (36%) | 38 (36.5%) | 9 (33%) | |
| 1/WK | 1 (1%) | 1 (1%) | 0 | |
| 2/WK | 46 (35%) | 37 (35.5%) | 9 (33%) | |
| Clinical Presentation | ||||
| Asymptomatic n (%) | 34 (26%) | 34 (33%) | 0 | <0.001 |
| Symptomatic n (%) | 97 (74%) | 70 (67%) | 27 (100%) | |
| Duration in days (median; range) | 5 (1-12) | 4 (1-12) | 5 (2-10) | 0.003 |
| Symptoms at Admission n (%) | ||||
| Fever | 52 (40%) | 37 (35.5%) | 15 (55.5%) | 0.062 |
| Cough | 43 (33%) | 35 (34%) | 8 (30%) | 0.691 |
| Dyspnea | 65 (50%) | 42 (40%) | 23 (85%) | <0.001 |
| Gastrointestinal Symptoms | 19 (14.5%) | 16 (15%) | 3 (11%) | 0.576 |
| Encephalopathy | 9 (7%) | 1 (1%) | 8 (30%) | <0.001 |
| Fluid Overload (anasarca/edema) | 10 (7%) | 6 (6%) | 4 (15%) | 0.127 |
| Investigations (mean; SD) | ||||
| Haemoglobin (g%) | 8.78±1.77 | 8.81±1.76 | 8.65±1.87 | 0.671 |
| Total leucocyte count (/cmm) | 7,854±4,067 | 7,022±2,935 | 11,059±5,929 | <0.001 |
| Platelet count (/cmm) | 1,97,916±1,06,528 | 2,01,452±1,07,853 | 1,84,296±1,02,064 | 0.455 |
| Serum creatinine (mg%) | 11.28±6.47 | 11.59±7.03 | 10.07±3.42 | 0.285 |
| Serum sodium (mEq/L) | 137±4.54 | 137±4.21 | 137±5.71 | 0.964 |
| Serum potassium (mEq/L) | 5.0±0.96 | 4.99±0.95 | 5.05±1.01 | 0.753 |
| Chest X ray n (%) | ||||
| Normal | 70 (53%) | 69 (66%) | 1 (4%) | |
| Bilateral opacities | 46 (35%) | 21 (20%) | 25 (93%) | <0.001 |
| Unilateral opacities | 8 (6%) | 7 (7%) | 1 (4%) | 0.056 |
| Pleural Effusion | 7 (5%) | 7 (7%) | 0 | |
| Clinical course n (%) | ||||
| No oxygen requirement | 76 (58%) | 74 (71%) | 2 (7%) | <0.001 |
| Requiring oxygen | 55 (42%) | 30 (29%) | 25 (93%) | <0.001 |
| Requiring inotropes | 11 (8%) | 1 (1%) | 10 (37%) | <0.001 |
| Treatment n (%) | ||||
| Hydroxychloroquine | 65 (50%) | 51 (49%) | 14 (52%) | Not req |
| Azithromycin | 82 (63%) | 61 (59%) | 21 (78%) | Not req |
| Oseltamavir | 8 (6%) | 2 (2%) | 6 (22%) | Not req |
| Antibiotics | 75 (57%) | 54 (52%) | 21 (78%) | Not req |
| Ivermectin | 23 (17.5%) | 16 (15%) | 7 (26%) | Not req |
| Lopinavir | 14 (10.7%) | 9 (9%) | 5 (18.5%) | Not req |
| Steroid | 9 (7%) | 5 (5%) | 4 (15%) | Not req |
DM: Diabetes Mellitus CAD: Coronary Artery Disease SLE: Systemic Lupus Erythematosus HBV: Hepatitis B Virus HCV: Hepatitis C Virus HIV: Human Immunodeficiency Virus